FDA ADVERSE DRUG REACTION REPORTING REVISED GUIDELINES
FDA ADVERSE DRUG REACTION REPORTING REVISED GUIDELINES will be available within a year, FDA Office of Epidemiology and Biometrics Director Gerald Faich, MD/MPH hold a Drug Information Assn. (DIA) workshop held in Bethesda, Md. Oct. 18-20. Noting that FDA has spent the last year "fixing the processing and the outputting" of its adverse drug reaction (ADR) reporting system, Faich said that over the next year the agency will "almost certainly change the 1639 form in a variety of ways, some big and some small." More importantly, he commented, FDA will change or recommend a change in guidelines for ADR reporting. Faich said the guidelines will "specify more clearly . . . which drugs we're really talking about, and for what period of time we are talking about, and which reactions we are talking about." He noted that the lack of standardized terms in ADR reporting is a problem. For example, he suggested that instead of using the term "serious" to describe an ADR, that "death" or "hospitalization" would more clearly describe the reaction. The DIA workshop on "International Adverse Drug Reaction Surveillance" involved approximately 350 registrants, one-third of which were from outside the U.S. The agenda included presentations on eight drug epidemiology systems, including those of Upjohn, Burroughs Wellcome, Kaiser Permanente, and a system developed in Saskatchewan, Canada. FDA Deputy Com. Novitch said that to help handle increasing ADRS, which could reach 100,000 reports in a year, FDA is "completing an arrangement with the American Medical Assn. that will allow us automatic access to their own physician reporting system."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth